2.71 USD
+0.05 (+1.88%)
BTMD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. BTMD has an average financial health and profitability rating. BTMD is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
BTMD had positive earnings in the past year.
In the past year BTMD had a positive cash flow from operations.
Of the past 5 years BTMD 4 years were profitable.
Of the past 5 years BTMD 4 years had a positive operating cash flow.
1.2 Ratios
BTMD has a Return On Assets of 25.87%. This is amongst the best in the industry. BTMD outperforms 98.44% of its industry peers.
Looking at the Return On Invested Capital, with a value of 45.22%, BTMD belongs to the top of the industry, outperforming 99.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.87% | ||
| ROE | N/A | ||
| ROIC | 45.22% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BTMD has a better Profit Margin (14.72%) than 86.98% of its industry peers.
BTMD's Profit Margin has declined in the last couple of years.
The Operating Margin of BTMD (16.09%) is better than 85.42% of its industry peers.
In the last couple of years the Operating Margin of BTMD has declined.
BTMD has a better Gross Margin (72.23%) than 78.65% of its industry peers.
In the last couple of years the Gross Margin of BTMD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.09% | ||
| PM (TTM) | 14.72% | ||
| GM | 72.23% |
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BTMD is creating value.
The number of shares outstanding for BTMD has been reduced compared to 1 year ago.
BTMD has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.33 indicates that BTMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.33, BTMD is doing good in the industry, outperforming 64.06% of the companies in the same industry.
The Debt to FCF ratio of BTMD is 4.18, which is a neutral value as it means it would take BTMD, 4.18 years of fcf income to pay off all of its debts.
BTMD's Debt to FCF ratio of 4.18 is amongst the best of the industry. BTMD outperforms 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.18 | ||
| Altman-Z | 2.33 |
ROIC/WACC5.05
WACC8.96%
2.3 Liquidity
BTMD has a Current Ratio of 1.01. This is a normal value and indicates that BTMD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.01, BTMD is doing worse than 81.77% of the companies in the same industry.
BTMD has a Quick Ratio of 1.01. This is a bad value and indicates that BTMD is not financially healthy enough and could expect problems in meeting its short term obligations.
BTMD has a Quick ratio of 0.72. This is amonst the worse of the industry: BTMD underperforms 86.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.72 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 190.00% over the past year.
Measured over the past years, BTMD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -48.53% on average per year.
The Revenue for BTMD has decreased by -18.44% in the past year. This is quite bad
BTMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.38% yearly.
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
Revenue 1Y (TTM)-18.44%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%
3.2 Future
BTMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.78% yearly.
The Revenue is expected to grow by 6.82% on average over the next years.
EPS Next Y166.59%
EPS Next 2Y24.94%
EPS Next 3Y24.88%
EPS Next 5Y42.78%
Revenue Next Year-2.93%
Revenue Next 2Y0.89%
Revenue Next 3Y2.93%
Revenue Next 5Y6.82%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 3.11, which indicates a rather cheap valuation of BTMD.
BTMD's Price/Earnings ratio is rather cheap when compared to the industry. BTMD is cheaper than 97.92% of the companies in the same industry.
BTMD is valuated cheaply when we compare the Price/Earnings ratio to 26.15, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 7.89, which indicates a rather cheap valuation of BTMD.
BTMD's Price/Forward Earnings ratio is rather cheap when compared to the industry. BTMD is cheaper than 92.19% of the companies in the same industry.
BTMD is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.12, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.11 | ||
| Fwd PE | 7.89 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BTMD is valued cheaply inside the industry as 93.23% of the companies are valued more expensively.
BTMD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BTMD is cheaper than 97.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.89 | ||
| EV/EBITDA | 7 |
4.3 Compensation for Growth
BTMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BTMD may justify a higher PE ratio.
A more expensive valuation may be justified as BTMD's earnings are expected to grow with 24.88% in the coming years.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y24.94%
EPS Next 3Y24.88%
5. Dividend
5.1 Amount
BTMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:BTMD (11/28/2025, 11:53:50 AM)
2.71
+0.05 (+1.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners64.32%
Inst Owner Change-8.25%
Ins Owners9.75%
Ins Owner Change0%
Market Cap133.98M
Revenue(TTM)195.65M
Net Income(TTM)28.79M
Analysts81.82
Price Target5.2 (91.88%)
Short Float %3.35%
Short Ratio7.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)270.4%
Min EPS beat(2)178.65%
Max EPS beat(2)362.15%
EPS beat(4)3
Avg EPS beat(4)249.23%
Min EPS beat(4)-1.96%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)105.05%
EPS beat(12)7
Avg EPS beat(12)16.44%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.43%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)-1.55%
Revenue beat(4)1
Avg Revenue beat(4)-1.97%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.65%
Revenue beat(12)4
Avg Revenue beat(12)-1.32%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.74%
PT rev (3m)-5.74%
EPS NQ rev (1m)14.7%
EPS NQ rev (3m)-18.75%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-2.82%
Revenue NQ rev (3m)-2.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.11 | ||
| Fwd PE | 7.89 | ||
| P/S | 0.68 | ||
| P/FCF | 3.89 | ||
| P/OCF | 3.35 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 7 |
EPS(TTM)0.87
EY32.1%
EPS(NY)0.34
Fwd EY12.67%
FCF(TTM)0.7
FCFY25.68%
OCF(TTM)0.81
OCFY29.85%
SpS3.96
BVpS-1.47
TBVpS-1.75
PEG (NY)0.02
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.87% | ||
| ROE | N/A | ||
| ROCE | 57.24% | ||
| ROIC | 45.22% | ||
| ROICexc | 92.24% | ||
| ROICexgc | 190.38% | ||
| OM | 16.09% | ||
| PM (TTM) | 14.72% | ||
| GM | 72.23% | ||
| FCFM | 17.59% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-32.05%
ROICexgc growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score7
Asset Turnover1.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.18 | ||
| Debt/EBITDA | 3.02 | ||
| Cap/Depr | 144.67% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 3.81 | ||
| Cash Conversion | 113.15% | ||
| Profit Quality | 119.51% | ||
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.72 | ||
| Altman-Z | 2.33 |
F-Score7
WACC8.96%
ROIC/WACC5.05
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
EPS Next Y166.59%
EPS Next 2Y24.94%
EPS Next 3Y24.88%
EPS Next 5Y42.78%
Revenue 1Y (TTM)-18.44%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%
Revenue Next Year-2.93%
Revenue Next 2Y0.89%
Revenue Next 3Y2.93%
Revenue Next 5Y6.82%
EBIT growth 1Y-29.68%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year32.82%
EBIT Next 3Y16.27%
EBIT Next 5Y14.88%
FCF growth 1Y43.63%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y53.94%
OCF growth 3Y10.29%
OCF growth 5Y12.28%
BIOTE CORP -A / BTMD FAQ
Can you provide the ChartMill fundamental rating for BIOTE CORP -A?
ChartMill assigns a fundamental rating of 5 / 10 to BTMD.
What is the valuation status of BIOTE CORP -A (BTMD) stock?
ChartMill assigns a valuation rating of 9 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.
Can you provide the profitability details for BIOTE CORP -A?
BIOTE CORP -A (BTMD) has a profitability rating of 6 / 10.
What is the expected EPS growth for BIOTE CORP -A (BTMD) stock?
The Earnings per Share (EPS) of BIOTE CORP -A (BTMD) is expected to grow by 166.59% in the next year.
Can you provide the dividend sustainability for BTMD stock?
The dividend rating of BIOTE CORP -A (BTMD) is 0 / 10 and the dividend payout ratio is 0%.